ReviewFrontiers in immunology2019
Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 87 citations in OpenAlex.
- Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention.NEJM evidence · 2024Trial
- Article
- Cost-Effectiveness of Venom Immunotherapy in Preventing Severe Bee and Wasp Sting Reactions.Allergy · 2026Article
- Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen.Nature communications · 2026Article
- Emergency response and clinical treatment analysis of a mass wasp sting incident involving 38 tourists: A case report.Medicine · 2026Article
- Acute Allergic Reactions and Severe Anaphylaxis: Underlying Causes, Management Strategies, and Future Directions.Archives of internal medicine research · 2026Article
- Low-dose allergen targeting to cDC2 induces long-term protection associated with induction of regulatory-like IL-10Frontiers in immunology · 2026Article
- Anaphylaxis after stings byHuman vaccines & immunotherapeutics · 2025Article
- Pattern of sensitization to yellow jacket venom and expression of recombinant antigen 5 (Ves v 5) from yellow jacket venom.BMC immunology · 2025Article
- In Vitro Assays for the Assessment of Safety and Toxicity in Pharmacopuncture Derived from Animal.Journal of pharmacopuncture · 2024Article
- Hymenoptera venom allergy in children.Italian journal of pediatrics · 2024Review
- A rare concurrence of acute tubular necrosis and chronic glomerular sclerosis in a patient with wasp stings.Heliyon · 2024Article
- The role of molecular diagnosis in anaphylactic patients with dual or triple-sensitization to Hymenoptera venoms.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Clinical characteristics, management, outcome, and cost of stings and bites in patients admitted to a tertiary care teaching hospital.Toxicology research · 2024Article
- Africanized honeybee venom (Frontiers in immunology · 2024Article
- Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy.Animals : an open access journal from MDPI · 2023Article
- Mast Cells and Basophils in IgE-Independent Anaphylaxis.International journal of molecular sciences · 2023Review
- Time-dependent cytokines changes in ultra-rush wasp venom immunotherapy.Scientific reports · 2023Article
- Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation.Journal of personalized medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hymenoptera stings may cause both local and systemic allergic reactions and even life threatening anaphylaxis. Along with pharmaceutical drugs and foods, hymenoptera venom is one of the most common causes of anaphylaxis in humans. To date, no parameter has been identified that may predict which sensitized people will have a future systemic sting reaction (SSR), however some risk factors, such as mastocytosis and age >40 years are known. Venom immunotherapy (VIT) is the most effective method of treatment for people who had SSR, which is shown to be effective even after discontinuation of the therapy. Development of peripheral tolerance is the main mechanism during immunotherapy. It is mediated by the production of blocking IgG/IgG4 antibodies that may inhibit IgE dependent reactions through both high affinity (FcεRI) and low affinity (FcεRII) IgE receptors on mast cells, basophils and B cells. The generation of antigen specific regulatory T cells produces IL-10 and suppresses Th2 immunity and the immune responses shift toward a Th1-type response. B regulatory cells are also involved in the production of IL-10 and the development of long term immune tolerance. During VIT the number of effector cells in target organs also decreases, such as mast cells, basophils, innate type 2 lymphocytes and eosinophils. Several meta-analyses and randomized controlled studies have proved that VIT is effective for preventing SSR to a sting and improves the quality of life. In this review, the risk of SSR in venom allergy and how VIT changed this risk are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.